Omeros Corporation (OMER)
NASDAQ: OMER · Real-Time Price · USD
9.20
-0.95 (-9.36%)
At close: Dec 15, 2025, 4:00 PM EST
9.16
-0.04 (-0.43%)
Pre-market: Dec 16, 2025, 8:39 AM EST
Omeros Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
202
Market Cap
652.28M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 29.87M | -34.96M | -53.93% |
| Dec 31, 2017 | 64.83M | 23.21M | 55.77% |
| Dec 31, 2016 | 41.62M | 28.11M | 208.07% |
| Dec 31, 2015 | 13.51M | 12.97M | 2,406.31% |
| Dec 31, 2014 | 539.00K | -1.06M | -66.31% |
| Dec 31, 2013 | 1.60M | -4.42M | -73.43% |
| Dec 31, 2012 | 6.02M | 1.50M | 33.11% |
| Dec 31, 2011 | 4.52M | 2.42M | 114.92% |
| Dec 31, 2010 | 2.11M | 661.00K | 45.78% |
| Dec 31, 2009 | 1.44M | 274.00K | 23.42% |
| Dec 31, 2008 | 1.17M | -753.00K | -39.16% |
| Dec 31, 2007 | 1.92M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
OMER News
- 15 days ago - Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906) - Business Wire
- 4 weeks ago - Omeros Corporation (OMER) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Omeros Corporation Reports Third Quarter 2025 Financial Results - Business Wire
- 5 weeks ago - Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025 - Business Wire
- 2 months ago - Omeros: Novo Nordisk Deal Highlights MASP-3 Alternative Pathway Targeting - Seeking Alpha
- 2 months ago - Omeros: Novo Nordisk's Licensing Deal Sends Shares Soaring, Makes Bull Case - Seeking Alpha
- 2 months ago - Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group - Business Wire
- 2 months ago - A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now? - The Motley Fool